Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
March 14, 2023 16:05 ET
|
Decibel Therapeutics, Inc.
- Received clearance from US FDA for IND and from UK MHRA for CTA to initiate CHORD™, a global Phase 1/2 dose escalation clinical trial of DB-OTO in pediatric patients - - Plan to initiate the...
Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
February 16, 2023 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting
February 09, 2023 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
January 24, 2023 07:00 ET
|
Decibel Therapeutics, Inc.
The CTA authorization for DB-OTO provides approval for the Company to expand its planned Phase 1/2 clinical trial to the U.K. in patients two years of age and younger One-time administration of...
Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update
November 09, 2022 16:45 ET
|
Decibel Therapeutics, Inc.
- Received FDA Clearance of IND Application for DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss - - Announced Submission of CTAs...
Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO
November 02, 2022 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss
October 17, 2022 07:00 ET
|
Decibel Therapeutics, Inc.
The IND for DB-OTO provides clearance for the Company to initiate a pediatric Phase 1/2 clinical trial in the U.S. in children and infants, and is part of an international regulatory...
Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors
October 12, 2022 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
September 22, 2022 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO
September 20, 2022 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...